Property & Construction

Abingdon: Evotec expands further at Milton Park

Published by
TBM Team

Evotec, a leading drug discovery alliance and development partnership company, has taken additional office and laboratory space at Milton Park, one of the leading science and technology communities in Europe, to bring its total occupation to 192,745 sq ft, making it one of the largest occupiers on the Park.

Evotec has had a presence in Milton Park ever since the company’s merger with Oxford Asymmetry International plc back in 2000. Oxford Asymmetry International had been based at Milton Park since 1989 in various guises and started in one of the original ex-MOD depot buildings.

Evotec’s latest letting for expansion space, which totals 16,823 sq ft at 90 Park Drive, has meant that it is now one of the largest occupiers at Milton Park alongside other companies such as Immunocore and Adaptimmune, which also started life at Milton Park in the old white buildings as University of Oxford spin-outs.

Christophe Muller, PhD, head of Evotec’s Milton Park site and EVP global head of business development, said: “Milton Park is an integral part of Evotec’s history and more than ever its future. The current expansion has been driven by an increased demand of our high-end drug discovery services, specifically in the areas of biological and protein sciences. The additional footprint, in bespoke facilities on Milton Park, as well as the recruitment of scientific experts, are also part of our plans to develop a fully integrated platform and centre of excellence for structure-based drug discovery in the UK.”

Philip Campbell, commercial director, MEPC commercial director, Milton Park said: “We congratulate Evotec on their impressive and continued expansion. What started as an Oxford University spin-out 30 years ago in a small depot has grown to become one of our largest occupiers employing approximately 600 people, as well as many others around the world. They are a great success story and we are really proud to be able to support them in their continued quest for drug discovery alliances and innovation across many disease areas which have significant impacts for people across the globe.”

From left: Christophe Muller and Philip Campbell

TBM Team

Recent Posts

Halma acquires safety tech firm MK Test in £44m deal

Buckinghamshire tech company Halma has acquired transport safety firm MK Test Systems Limited. Headquartered in…

3 hours ago

Paragon Bank provide finance for West Sussex housing development

BRiCS Development has secured an £11.55 million finance facility with Paragon Bank’s Development Finance team…

3 hours ago

IT firm Mintivo appoints new Managing Director

IT services and solutions company Mintivo has appointed Alex Jukes as its new Managing Director…

3 hours ago

Bartlett Tree Experts to build new research facility in Wokingham woodland

Bartlett Tree Experts have announced its intention to build a new arboretum and research facility…

4 hours ago

New £3m imaging system to be developed at University of Surrey

The creation of a first-of-its-kind imaging system at the University of Surrey could help the…

4 hours ago

New chair of trustees at Open Sight Hampshire

Open Sight, which provides support across Hampshire to those living with or at risk of…

6 hours ago